rates with HMG/IUI therapy; particularly for women aged 0084, USA Ͼ35 years. Furthermore, there are conflicting data on the impact of male partner age on pregnancy rates with infertility This study analyses the influence of female and male therapy (Galle et al., 1990; Piette et al., 1990 ; Mathieu et al., patient age and human menopausal gonadotrophin (HMG) 1995). There are no data examining the effect of male requirements on clinical pregnancy rates and live birth partner age and pregnancy rates with HMG/IUI treatment. The rates with ovulation stimulation using HMG in combination objectives of this study were firstly, to examine the relationship with intrauterine insemination (IUI). In this study, 363 of female and male partner age on clinical pregnancy rates consecutive HMG/IUI treatment cycles in 184 patients and live birth rates with HMG/IUI therapy and secondly, to carried out at a university fertility centre were analysed in determine whether a critical threshold exists between menoa retrospective fashion. The main outcomes measured were trophin requirements and clinical pregnancy rates with this clinical pregnancy rates and live birth rates. Increased therapy. female partner age (ജ35) and male partner age (ജ40) were found to negatively influence pregnancy rates with HMG/ IUI therapy. In addition, this study demonstrated a critical Materials and methods threshold of HMG requirements beyond which pregnancy Key words: HMG/intrauterine insemination/patient age/pregwritten consent was obtained prior to initiating therapy as part of an nancy rates institutional review board approved protocol. All patients included in this study previously received ജthree unsuccessful ovulatory treatment cycles with CC/IUI therapy. A midluteal serum progesterone concentration of Ͼ10 ng/ml was considered to be indicative of an
rates with HMG/IUI therapy; particularly for women aged 0084, USA Ͼ35 years. Furthermore, there are conflicting data on the impact of male partner age on pregnancy rates with infertility This study analyses the influence of female and male therapy (Galle et al., 1990; Piette et al., 1990; Mathieu et al. , patient age and human menopausal gonadotrophin (HMG) 1995). There are no data examining the effect of male requirements on clinical pregnancy rates and live birth partner age and pregnancy rates with HMG/IUI treatment. The rates with ovulation stimulation using HMG in combination objectives of this study were firstly, to examine the relationship with intrauterine insemination (IUI). In this study, 363 of female and male partner age on clinical pregnancy rates consecutive HMG/IUI treatment cycles in 184 patients and live birth rates with HMG/IUI therapy and secondly, to carried out at a university fertility centre were analysed in determine whether a critical threshold exists between menoa retrospective fashion. The main outcomes measured were trophin requirements and clinical pregnancy rates with this clinical pregnancy rates and live birth rates. Increased therapy. female partner age (ജ35) and male partner age (ജ40) were found to negatively influence pregnancy rates with HMG/ IUI therapy. In addition, this study demonstrated a critical Materials and methods threshold of HMG requirements beyond which pregnancy otrophins (HMG) with intrauterine insemination (IUI) is an of a few couples where the female age was Ͼ40 years, where therapy was initiated following 6 months of the inability to conceive. The established treatment regimen for patients undergoing infertility infertility evaluation consisted of an assessment of ovulation, semen therapy. This ovulation stimulation protocol has been shown analysis, evaluation of the luteal phase and confirmation of tubal to be an effective treatment regimen for patients with a variety patency (hysterosalpingogram and/or laparoscopy). Laparoscopy was of infertility diagnoses (Dodson and Haney, 1991) . Despite performed in a selective manner consistent with published protocols the broad acceptance of this treatment modality, there are (Navot et al., 1987; Collins and Rowe, 1989 males aged Ͻ40 years whose female partners were ജ35 years Inseminations were timed by the administration of human chorionic gonadotrophin (HCG) (5000-10 000 IU) (Profasi; Serono Laborat-(16.3 versus 6.5%, P ϭ 0.02). No differences were observed ories, Randolph, MA, USA) when the lead follicle(s) attained a mean in the clinical pregnancy rates in treatment cycles in which diameter of 16 mm. Single inseminations were performed~36 h males aged ജ40 years were compared with males aged Ͻ40 following HCG administration. A total volume of 0.3-0.5 ml was years whose female partners were aged Ͻ35 years, P ϭ 0.81. inseminated in all cases following standard swim-up procedure as Furthermore, the mean inseminating sperm concentrations did described by Dodson et al. (1987) . Initial serum HCG quantifications not differ between males of Ͻ40 years compared with males were performed 16 days following IUI in those women without aged ജ40 years (35.0 Ϯ 3.0ϫ10 6 /ml versus 35.3 Ϯ 3.3ϫ10 6 / menses to confirm pregnancy. ml, P ϭ 0.94). In addition, the mean inseminating sperm concentrations did not differ between conception and nonOutcome conception cycles (39.1 Ϯ 5.9ϫ10 6 /ml versus 34.3 Ϯ 2.4ϫ10 6 / Clinical pregnancy was defined as the detection of fetal cardiac ml, P ϭ 0.45). female partner was aged Ͼ40 years no pregnancies occurred
Statistical analysis
when Ͼ20 ampoules (1500 IU) were necessary to achieve Proportions were compared using χ 2 analysis and exact permutational follicular maturity. In women aged Ͻ35 years, 5.1% of P values were computed. A Kaplan-Meier Life years utilized Ͼ25 ampoules to achieve follicular maturity. In ampoules (75 IU) of menotrophins (16.8 Ϯ 5.0 versus 15.5 Ϯ 5.7, P ϭ 0.34), between conception and non-conception cycles.
Results
Fewer ampoules (75 IU) of menotrophins were required for follicular maturation in treatment cycles resulting in concepIn this series, 363 treatment cycles in 184 patients resulted in 44 clinical pregnancies for an overall clinical pregnancy rate tion, compared with non-conception cycles in women ജ35 years, (16.2 Ϯ 4.5 versus 20.2 Ϯ 10.3, P ϭ 0.05). of 12.1% per treatment cycle. There was no difference in the mean female patient age or the clinical pregnancy rates between As shown in Figure 1 , treatment cycles requiring 16-25 ampoules (1200-1875 IU) of menotrophins had significantly different infertility diagnoses, P ജ0.15. is shown as a function of the number of menotrophin ampoules c Age 35-40 years versus Ͼ40 years (P Ͻ0.02).
(75 IU) required to achieve follicular maturity for women aged d Age Ͻ35 years versus ജ35 years (P ഛ0.004).
Ͻ35 years (solid bars) compared with women aged ജ35 years (hatched bars). *Significant difference in the clinical pregnancy rate between women aged Ͻ35 years in comparison with women aged ജ35 years (P ϭ 0.02). **Significant difference in the clinical Jewelewicz, 1986; Menken et al., 1986; Pearlstone et al., b Values are percentages (%).
1992; Magarelli et al., 1996) . Recently, a large case-control study in women undergoing in-vitro fertilization (IVF) with intracytoplasmic sperm injection demonstrated a significantly ascertain whether a critical threshold exists between menotrob Males Ͻ40 years versus ജ40 years when females Ͻ35 years old phin requirements and clinical pregnancy rates in patients (P ϭ 0.81). c Males Ͻ40 years versus ജ40 years when females ജ35 years old receiving this therapy. This study revealed a profound decline
in clinical pregnancy rates and live birth rates with increasing age of the female partner. A significant decline in clinical pregnancy rates was also observed with increasing male partner higher clinical pregnancy rates in women aged Ͻ35 years in comparison with women aged ജ35 years (P ϭ 0.02 and P ഛ age when the female partner was ജ35 years. Finally, this study demonstrated a relationship between menotrophin requirements 0.04, see Figure 1 ). The mean number of days of menotrophin stimulation needed to achieve follicular maturity was less in and clinical pregnancy rates in patients receiving HMG/ IUI therapy. conception versus non-conception cycles when the female partner was aged Ͻ35 years, (8.6 Ϯ 1.8 days versus 10.2 Ϯ Controlled ovarian stimulation with HMG in combination with IUI is an established treatment protocol for patients 2.6 days, P Ͻ0.01). However, there was no difference in the mean number of days of menotrophin stimulation in conception undergoing ovulation induction therapy (Dodson et al., 1991) . This regimen is frequently utilized in patients who fail to versus non-conception cycles when the female partner was ജ35 years (8.3 Ϯ 1.6 days versus 8.6 Ϯ 2.0 days, P ϭ conceive with CC/IUI and/or sequential CC/HMG/IUI therapy prior to initiating assisted reproductive technologies (Corsan 0.52). There was no difference between the maximum serum oestradiol concentration, the mean endometrial thickness, or and Kemmann, 1991) . The decline in pregnancy rates with HMG/IUI therapy in females ജ35 years is consistent with our the mean number of mature follicles between the conception and non-conception treatment cycles in women in the Ͻ35 or earlier reports which revealed a substantial decline in pregnancy rates using CC/IUI and/or sequential CC/HMG/IUI therapy ജ35 year age groups, P ജ0.29. Agarwal and Bugalos, 1996; Brzechffa et al., 1996) . There IVF and embryo transfer observed no adverse effect of male partner age on pregnancy rates after controlling for female are limited data evaluating the impact of female partner age on pregnancy rates using HMG/IUI therapy (Dodson and partner age (Piette et al., 1990) . This study is the first to document the existence of a critical Haney, 1991; Dickey et al., 1993) . Furthermore, the vast majority of patients in these reports were ഛ39 years of age.
threshold between menotrophin requirements and pregnancy rates in patients receiving HMG/IUI therapy. Patients who A recent study in women ജ40 years of age undergoing controlled ovarian stimulation with IUI reported no viable required Ͼ25 ampoules (1875 IU) of menotrophins to achieve follicular maturity failed to conceive with this therapy, indepregnancies in women aged ജ43 years (Corsan et al., 1996) . In contrast, this study evaluates a broader spectrum of repropendent of female patient age. The decline in reproductive capacity in the human female has been attributed to a depletion ductive aged females, in which approximately one-third of female partners were Ͼ40 years of age. Thus, these data are in the follicular pool (Aschheim, 1979) , a deterioration in oocyte quality (Peluso et al., 1982; Schwartz and Mayaux, valuable for counselling the increasing percentage of couples who electively delay childbearing.
1982; Gindoff and Jewelewicz, 1986; Stovall et al., 1991) , and reduced sensitivity of the follicular apparatus to menotrophin Studies which have addressed the influence of male partner age on pregnancy rates in couples undergoing infertility therapy stimulation (Menken et al., 1986; Pearlstone et al., 1992) . Based on these observations we conclude that HMG/IUI cycles have been inconclusive (Galle et al., 1990; Piette et al., 1990) . Furthermore, there are no data examining the significance of which require Ͼ25 ampoules of menotrophins portend a poor prognosis for conception and reflect a reduction in male partner age on treatment cycle outcome in patients receiving HMG/IUI therapy which control for the age of the reproductive capacity. In summary, this study demonstrates that both increased female partner. This study demonstrates a marked decline in clinical pregnancy rates with increasing male partner age after female and male partner age contribute to the decline in clinical pregnancy rates and live birth rates with HMG/IUI controlling for female partner age. When the female partner was ജ35 years of age, a significant decline in clinical pregnancy therapy. In addition, menotrophin requirements increase with advancing age of the female partner and significantly influence rates was observed when the male partner was ജ40 years. Furthermore, the inseminating sperm concentrations were simclinical pregnancy rates with this treatment regimen. Importantly, a critical threshold exists between menotrophin requireilar between younger (Ͻ40 years) and older (ജ40 years) males as well as between conception and non-conception cycles.
ments and the ability to achieve a clinical pregnancy, and this threshold declines with increasing female partner age. This Thus, the decline in pregnancy rates as a function of increasing paternal age cannot be attributed to differences in insemination information should be useful for counselling infertile couples of all ages, and provides valuable information for the increasing sperm concentrations. Our observation that male partner age ജ40 years may negatively impact pregnancy rates with HMG/ number of couples who delay childbearing. IUI therapy is supported by several reports. An epidemiological study which examined fecundity rates in fertile couples prior to 1911 in Ireland, reported decreased fecundity rates when
